Cite
HARVARD Citation
Planchard, D. et al. (n.d.). LBA51Phase 2 trial (BRF113928) of dabrafenib (D) plus trametinib (T) in patients (pts) with previously untreated BRAF V600E–mutant metastatic non-small cell lung cancer (NSCLC). Annals of oncology. p. . [Online].